Raloxifene (BioDeep_00000002326)

 

Secondary id: BioDeep_00001867796

human metabolite blood metabolite PANOMIX_OTCML-2023 Chemicals and Drugs


代谢物信息卡片


(2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone

化学式: C28H27NO4S (473.1661)
中文名称: 雷洛昔芬
谱图信息: 最多检出来源 Chinese Herbal Medicine(otcml) 49.73%

分子结构信息

SMILES: C1CCN(CC1)CCOc1ccc(cc1)C(=O)c1c2ccc(cc2sc1c1ccc(cc1)O)O
InChI: InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2

描述信息

Raloxifene is only found in individuals that have used or taken this drug. It is a second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. [PubChem]. Raloxifene binds to estrogen receptors, resulting in differential expression of multiple estrogen-regulated genes in different tissues. Raloxifene produces estrogen-like effects on bone, reducing resorption of bone and increasing bone mineral density in postmenopausal women, thus slowing the rate of bone loss. The maintenance of bone mass by raloxifene and estrogens is, in part, through the regulation of the gene-encoding transforming growth factor-β3 (TGF-β3), which is a bone matrix protein with antiosteoclastic properties. Raloxifene activates TGF-β3 through pathways that are estrogen receptor-mediated but involve DNA sequences distinct from the estrogen response element. The drug also binds to the estrogen receptor and acts as an estrogen agonist in preosteoclastic cells, which results in the inhibtion of their proliferative capacity. This inhibition is thought to contribute to the drugs effect on bone resorption. Other mechanisms include the suppression of activity of the bone-resorbing cytokine interleukin-6 promoter activity. Raloxifene also antagonizes the effects of estrogen on mammary tissue and blocks uterotrophic responses to estrogen. By competing with estrogens for the estrogen receptors in reproductive tissue, raloxifene prevents the transcriptional activation of genes containing the estrogen response element. As well, raloxifene inhibits the estradiol-dependent proliferation of MCF-7 human mammary tumor cells in vitro. The mechansim of action of raloxifene has not been fully determined, but evidence suggests that the drugs tissue-specific estrogen agonist or antagonist activity is related to the structural differences between the raloxifene-estrogen receptor complex (specifically the surface topography of AF-2) and the estrogen-estrogen receptor complex. Also, the existence of at least 2 estrogen receptors (ERα, ERβ) may contribute to the tissue specificity of raloxifene.
CONFIDENCE standard compound; INTERNAL_ID 236; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3671; ORIGINAL_PRECURSOR_SCAN_NO 3667
CONFIDENCE standard compound; INTERNAL_ID 236; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7479; ORIGINAL_PRECURSOR_SCAN_NO 7477
CONFIDENCE standard compound; INTERNAL_ID 236; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3606; ORIGINAL_PRECURSOR_SCAN_NO 3604
CONFIDENCE standard compound; INTERNAL_ID 236; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3605; ORIGINAL_PRECURSOR_SCAN_NO 3603
CONFIDENCE standard compound; INTERNAL_ID 236; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7456; ORIGINAL_PRECURSOR_SCAN_NO 7455
CONFIDENCE standard compound; INTERNAL_ID 236; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7507; ORIGINAL_PRECURSOR_SCAN_NO 7505
CONFIDENCE standard compound; INTERNAL_ID 236; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7491; ORIGINAL_PRECURSOR_SCAN_NO 7487
CONFIDENCE standard compound; INTERNAL_ID 236; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7503; ORIGINAL_PRECURSOR_SCAN_NO 7502
CONFIDENCE standard compound; INTERNAL_ID 236; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7515; ORIGINAL_PRECURSOR_SCAN_NO 7513
CONFIDENCE standard compound; INTERNAL_ID 236; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3597; ORIGINAL_PRECURSOR_SCAN_NO 3594
CONFIDENCE standard compound; INTERNAL_ID 236; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3612; ORIGINAL_PRECURSOR_SCAN_NO 3610
CONFIDENCE standard compound; INTERNAL_ID 236; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3602; ORIGINAL_PRECURSOR_SCAN_NO 3597
G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03X - Other sex hormones and modulators of the genital system > G03XC - Selective estrogen receptor modulators
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator
C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist
CONFIDENCE standard compound; INTERNAL_ID 2754
CONFIDENCE standard compound; INTERNAL_ID 8536
D050071 - Bone Density Conservation Agents
C1892 - Chemopreventive Agent
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].

同义名列表

18 个代谢物同义名

(2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone; 2-(4-hydroxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]benzoyl}-1-benzothiophen-6-ol; Raloxifene hydrochloride; Keoxifene hydrochloride; Raloxifene Hcl; Raloxifenum; Raloxifeno; Raloxifene; LY 139481; LY-139481; Keoxifene; Eviden; Evista; Raxeto; RAL; LY156758 (free base); LY139481; Raloxifene



数据库引用编号

39 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 13 ABCB1, AR, BGLAP, BRCA1, CALCA, ESR1, MAPK14, PGR, PRL, PTGS2, TBX20, TNFSF11, TP53
Peripheral membrane protein 3 CYP1B1, ESR1, PTGS2
Endoplasmic reticulum membrane 4 CYP19A1, CYP1B1, PTGS2, UGT1A1
Nucleus 9 AR, BRCA1, ESR1, ESR2, MAPK14, PGR, PRL, TBX20, TP53
cytosol 5 AR, ESR1, MAPK14, PGR, TP53
dendrite 1 BGLAP
nuclear body 1 BRCA1
centrosome 1 TP53
nucleoplasm 8 AR, BRCA1, ESR1, ESR2, MAPK14, PGR, PRL, TP53
RNA polymerase II transcription regulator complex 1 PRL
Cell membrane 3 ABCB1, ESR1, TNFSF11
Cytoplasmic side 1 ESR1
Multi-pass membrane protein 2 ABCB1, CYP19A1
cell surface 1 ABCB1
glutamatergic synapse 1 MAPK14
Golgi apparatus 1 ESR1
neuronal cell body 1 CALCA
plasma membrane 7 ABCB1, AR, BRCA1, ESR1, PGR, TNFSF11, UGT1A1
terminal bouton 1 CALCA
Membrane 9 ABCB1, AR, BRCA1, CYP19A1, CYP1B1, ESR1, TNFSF11, TP53, UGT1A1
apical plasma membrane 1 ABCB1
caveola 1 PTGS2
extracellular exosome 3 ABCB1, BMP3, SHBG
endoplasmic reticulum 4 CYP19A1, PTGS2, TP53, UGT1A1
extracellular space 6 BGLAP, BMP3, CALCA, PRL, PTH, TNFSF11
perinuclear region of cytoplasm 1 UGT1A1
mitochondrion 4 CYP1B1, ESR2, MAPK14, TP53
protein-containing complex 5 AR, BRCA1, ESR1, PTGS2, TP53
intracellular membrane-bounded organelle 2 CYP1B1, ESR2
Microsome membrane 3 CYP19A1, CYP1B1, PTGS2
Secreted 6 BGLAP, BMP3, CALCA, PRL, SHBG, TNFSF11
extracellular region 8 BGLAP, BMP3, CALCA, MAPK14, PRL, PTH, SHBG, TNFSF11
Single-pass membrane protein 1 UGT1A1
mitochondrial outer membrane 1 PGR
hippocampal mossy fiber to CA3 synapse 1 CALCA
Mitochondrion matrix 1 TP53
mitochondrial matrix 1 TP53
transcription regulator complex 2 ESR1, TP53
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome 1 TP53
perikaryon 1 BGLAP
nucleolus 1 TP53
Single-pass type II membrane protein 1 TNFSF11
vesicle 1 BGLAP
Apical cell membrane 1 ABCB1
Cytoplasm, perinuclear region 1 UGT1A1
Cytoplasm, cytoskeleton 1 TP53
Nucleus, PML body 1 TP53
PML body 1 TP53
nuclear speck 2 AR, MAPK14
Nucleus inner membrane 1 PTGS2
Nucleus outer membrane 1 PTGS2
nuclear inner membrane 1 PTGS2
nuclear outer membrane 1 PTGS2
neuron projection 1 PTGS2
chromatin 7 AR, ESR1, ESR2, PGR, PRL, TBX20, TP53
Chromosome 1 BRCA1
[Isoform 5]: Cytoplasm 1 BRCA1
spindle pole 1 MAPK14
site of double-strand break 1 TP53
endosome lumen 1 PRL
lateral element 1 BRCA1
euchromatin 1 ESR1
germ cell nucleus 1 TP53
replication fork 1 TP53
ubiquitin ligase complex 1 BRCA1
ficolin-1-rich granule lumen 1 MAPK14
secretory granule lumen 1 MAPK14
Golgi lumen 1 BGLAP
endoplasmic reticulum lumen 2 BGLAP, PTGS2
nuclear matrix 1 TP53
transcription repressor complex 1 TP53
male germ cell nucleus 1 BRCA1
XY body 1 BRCA1
neuronal dense core vesicle 1 CALCA
[Isoform 2]: Cytoplasm 1 TNFSF11
[Tumor necrosis factor ligand superfamily member 11, soluble form]: Secreted 1 TNFSF11
ribonucleoprotein complex 1 BRCA1
[Isoform 1]: Nucleus 2 ESR1, TP53
external side of apical plasma membrane 1 ABCB1
intracellular non-membrane-bounded organelle 1 BRCA1
DNA repair complex 1 BRCA1
BRCA1-C complex 1 BRCA1
[Isoform 4]: Mitochondrion outer membrane 1 PGR
endoplasmic reticulum chaperone complex 1 UGT1A1
cytochrome complex 1 UGT1A1
BRCA1-A complex 1 BRCA1
BRCA1-B complex 1 BRCA1
BRCA1-BARD1 complex 1 BRCA1
gamma-tubulin ring complex 1 BRCA1
nuclear ubiquitin ligase complex 1 BRCA1


文献列表

  • Victoria O Oyanna, Baron J Bechtold, Katherine D Lynch, M Ridge Call, Tyler N Graf, Nicholas H Oberlies, John D Clarke. Green Tea Catechins Decrease Solubility of Raloxifene In Vitro and Its Systemic Exposure in Mice. Pharmaceutical research. 2024 Mar; 41(3):557-566. doi: 10.1007/s11095-024-03662-w. [PMID: 38302834]
  • Saurabh Chugh, Prabhakar Tiwari, Charu Suri, Sonu Kumar Gupta, Padam Singh, Rania Bouzeyen, Saqib Kidwai, Mitul Srivastava, Nagender Rao Rameshwaram, Yashwant Kumar, Shailendra Asthana, Ramandeep Singh. Polyphosphate kinase-1 regulates bacterial and host metabolic pathways involved in pathogenesis of Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America. 2024 Jan; 121(2):e2309664121. doi: 10.1073/pnas.2309664121. [PMID: 38170746]
  • Anjali Pant, Gajanand Sharma, Sumant Saini, Gurjeet Kaur, Atul Jain, Anil Thakur, Bhupinder Singh. QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies. Drug delivery and translational research. 2023 Sep; ?(?):. doi: 10.1007/s13346-023-01427-3. [PMID: 37768530]
  • Shalvi Sinai Kunde, Sarika Wairkar. Folic acid anchored urchin-like raloxifene nanoparticles for receptor targeting in breast cancer: Synthesis, optimisation and in vitro biological evaluation. International journal of pharmaceutics. 2022 Jul; 623(?):121926. doi: 10.1016/j.ijpharm.2022.121926. [PMID: 35716974]
  • Mohammad Khaksari, Alireza Raji-Amirhasani, Hamideh Bashiri, Mohammad Navid Ebrahimi, Hossein Azizian. Protective effects of combining SERMs with estrogen on metabolic parameters in postmenopausal diabetic cardiovascular dysfunction: The role of cytokines and angiotensin II. Steroids. 2022 07; 183(?):109023. doi: 10.1016/j.steroids.2022.109023. [PMID: 35358567]
  • Daniela Iaconis, Licia Bordi, Giulia Matusali, Carmine Talarico, Candida Manelfi, Maria Candida Cesta, Mara Zippoli, Francesca Caccuri, Antonella Bugatti, Alberto Zani, Federica Filippini, Laura Scorzolini, Marco Gobbi, Marten Beeg, Arianna Piotti, Monica Montopoli, Veronica Cocetta, Silvia Bressan, Enrico M Bucci, Arnaldo Caruso, Emanuele Nicastri, Marcello Allegretti, Andrea R Beccari. Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants. Cell death & disease. 2022 May; 13(5):498. doi: 10.1038/s41419-022-04961-z. [PMID: 35614039]
  • Hae Won Lee, Woo Youl Kang, Wookjae Jung, Mi-Ri Gwon, Kyunghee Cho, Backhwan Lee, Sook Jin Seong, Young-Ran Yoon. Pharmacokinetic Drug Interaction Between Raloxifene and Cholecalciferol in Healthy Volunteers. Clinical pharmacology in drug development. 2022 05; 11(5):623-631. doi: 10.1002/cpdd.1062. [PMID: 34984851]
  • Anju Sharma, Jarriaun Streets, Priyanka Bhatt, Pranav Patel, Vijaykumar Sutariya, Sheeba Varghese Gupta. Formulation and Characterization of Raloxifene Nanostructured Lipid Carriers for Permeability and Uptake Enhancement Applications. Assay and drug development technologies. 2022 May; 20(4):164-174. doi: 10.1089/adt.2022.004. [PMID: 35617693]
  • Atul Jain, Teenu Sharma, Rajendra Kumar, O P Katare, Bhupinder Singh. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC. Drug delivery and translational research. 2022 05; 12(5):1136-1160. doi: 10.1007/s13346-021-00990-x. [PMID: 33966178]
  • Guilherme L Alves, Fernanda V Teixeira, Priscila Bianca Rodrigues da Rocha, Anna Paula Krawczyk-Santos, Lígia Marquez Andrade, Marcilio Cunha-Filho, Ricardo N Marreto, Stephânia F Taveira. Preformulation and characterization of raloxifene-loaded lipid nanoparticles for transdermal administration. Drug delivery and translational research. 2022 03; 12(3):526-537. doi: 10.1007/s13346-021-00949-y. [PMID: 33682031]
  • Francesco Caruso, Jens Z Pedersen, Sandra Incerpi, Sarjit Kaur, Stuart Belli, Radu-Mihai Florea, Miriam Rossi. Mechanism of Caspase-1 Inhibition by Four Anti-inflammatory Drugs Used in COVID-19 Treatment. International journal of molecular sciences. 2022 Feb; 23(3):. doi: 10.3390/ijms23031849. [PMID: 35163769]
  • Richa Mishra, Lalita Mohan Behera, Soumendra Rana. Binding of raloxifene to human complement fragment 5a (hC5a): a perspective on cytokine storm and COVID19. Journal of biomolecular structure & dynamics. 2022 02; 40(3):982-994. doi: 10.1080/07391102.2020.1820381. [PMID: 32930050]
  • Marcello Allegretti, Maria Candida Cesta, Mara Zippoli, Andrea Beccari, Carmine Talarico, Flavio Mantelli, Enrico M Bucci, Laura Scorzolini, Emanuele Nicastri. Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection. Cell death and differentiation. 2022 01; 29(1):156-166. doi: 10.1038/s41418-021-00844-6. [PMID: 34404919]
  • Nisha Mahey, Rushikesh Tambat, Nishtha Chandal, Dipesh Kumar Verma, Krishan Gopal Thakur, Hemraj Nandanwar. Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus. Microbiology spectrum. 2021 12; 9(3):e0095121. doi: 10.1128/spectrum.00951-21. [PMID: 34908453]
  • Xinhui Du, Na Gao, Xiaoyong Song. Bioadhesive polymer/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability. Drug delivery. 2021 Dec; 28(1):252-260. doi: 10.1080/10717544.2021.1872742. [PMID: 33501870]
  • Hao-Yang Ma, Shuang Chen, Ling-Ling Lu, Wei Gong, Ai-Hua Zhang. Raloxifene in the Treatment of Osteoporosis in Postmenopausal Women with End-Stage Renal Disease: A Systematic Review and Meta-Analysis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2021 Nov; 53(11):730-737. doi: 10.1055/a-1655-4362. [PMID: 34740274]
  • Hongying Li, Vinayak S Jamdade. Raloxifene impedes cisplatin-induced nephrotoxicity through inhibition of Proinflammatory cytokines in female wistar rats. Pakistan journal of pharmaceutical sciences. 2021 Nov; 34(6):2141-2147. doi: . [PMID: 35034874]
  • Yan Sun, Ying Xiong, Yong Liang Meng, Heitor O Santos, Felipe L Athayde, Ivan G O de Souza, Ling Yang. Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: A systematic review and meta-analysis of randomized controlled trials. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2021 Oct; 60-61(?):101421. doi: 10.1016/j.ghir.2021.101421. [PMID: 34384975]
  • Rodrigo R R Duarte, Dennis C Copertino, Luis P Iñiguez, Jez L Marston, Yaron Bram, Yuling Han, Robert E Schwartz, Shuibing Chen, Douglas F Nixon, Timothy R Powell. Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry. Molecular medicine (Cambridge, Mass.). 2021 09; 27(1):105. doi: 10.1186/s10020-021-00356-6. [PMID: 34503440]
  • Hong Shi, Heitor O Santos, Ivan G O de Souza, Gilles Jadd Hoilat, Carlos E C Martins, Hamed Kord Varkaneh, Joud Amer Alkhwildi, Aljawhara Talal Hejji, Faisal Almuqayyid, Ahmed Abu-Zaid. The Effect of Raloxifene Treatment on Lipid Profile in Elderly Individuals: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Clinical therapeutics. 2021 09; 43(9):297-317. doi: 10.1016/j.clinthera.2021.07.017. [PMID: 34462124]
  • Ka-Ying Wong, Liping Zhou, Wenxuan Yu, Christina Chui-Wa Poon, Huihui Xiao, Chi-On Chan, Daniel Kam-Wah Mok, Man-Sau Wong. Water extract of Er-xian decoction selectively exerts estrogenic activities and interacts with SERMs in estrogen-sensitive tissues. Journal of ethnopharmacology. 2021 Jul; 275(?):114096. doi: 10.1016/j.jep.2021.114096. [PMID: 33823166]
  • Takashi Hara, Yasukazu Hijikata, Yukiko Matsubara, Norio Watanabe. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D. The Cochrane database of systematic reviews. 2021 Jul; 7(?):CD013424. doi: 10.1002/14651858.cd013424.pub2. [PMID: 34231877]
  • Aditi Sharma, Lalit Sharma, Reena V Saini, Ashwani Kumar, Rohit Goyal. Pinus roxburghii alleviates bone porosity and loss in postmenopausal osteoporosis by regulating estrogen, calcium homeostasis and receptor activator of nuclear factor-κB, osteoprotegerin, cathepsin bone markers. The Journal of pharmacy and pharmacology. 2021 Jun; 73(7):901-915. doi: 10.1093/jpp/rgaa014. [PMID: 33769535]
  • Rašković Aleksandar, Paut Kusturica Milica, Mitić Gorana, Milijašević Boris, Stojšić-Milosavljević Anastazija, Lalić-Popović Mladena, Stević Snežana, Stilinović Nebojša, Gigov Slobodan. Interaction between apigenin and sodium deoxycholate with raloxifene: A potential risk for clinical practice. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2021 Jun; 161(?):105809. doi: 10.1016/j.ejps.2021.105809. [PMID: 33741473]
  • Shao-Hua Ping, Fa-Ming Tian, Hao Liu, Qi Sun, Li-Tao Shao, Qiang-Qiang Lian, Liu Zhang. Raloxifene inhibits the overexpression of TGF-β1 in cartilage and regulates the metabolism of subchondral bone in rats with osteoporotic osteoarthritis. Bosnian journal of basic medical sciences. 2021 Jun; 21(3):284-293. doi: 10.17305/bjbms.2020.5142. [PMID: 33259777]
  • Bruce Schultz, Andrea Zaliani, Christian Ebeling, Jeanette Reinshagen, Denisa Bojkova, Vanessa Lage-Rupprecht, Reagon Karki, Sören Lukassen, Yojana Gadiya, Neal G Ravindra, Sayoni Das, Shounak Baksi, Daniel Domingo-Fernández, Manuel Lentzen, Mark Strivens, Tamara Raschka, Jindrich Cinatl, Lauren Nicole DeLong, Phil Gribbon, Gerd Geisslinger, Sandra Ciesek, David van Dijk, Steve Gardner, Alpha Tom Kodamullil, Holger Fröhlich, Manuel Peitsch, Marc Jacobs, Julia Hoeng, Roland Eils, Carsten Claussen, Martin Hofmann-Apitius. A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization. Scientific reports. 2021 05; 11(1):11049. doi: 10.1038/s41598-021-90296-2. [PMID: 34040048]
  • Gengqi Wang, Wenqiang Xu, Junjie Zhang, Tian Tang, Jing Chen, Changchun Fan. Induction of Bone Remodeling by Raloxifene-Doped Iron Oxide Functionalized with Hydroxyapatite to Accelerate Fracture Healing. Journal of biomedical nanotechnology. 2021 May; 17(5):932-941. doi: 10.1166/jbn.2021.3068. [PMID: 34082878]
  • Nur-Vaizura Mohamad, Soelaiman Ima-Nirwana, Kok-Yong Chin. Therapeutic potential of annatto tocotrienol with self-emulsifying drug delivery system in a rat model of postmenopausal bone loss. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2021 May; 137(?):111368. doi: 10.1016/j.biopha.2021.111368. [PMID: 33582449]
  • Keiko Imamura, Yasuteru Sakurai, Takako Enami, Ran Shibukawa, Yohei Nishi, Akira Ohta, Tsugumine Shu, Jitsutaro Kawaguchi, Sayaka Okada, Thomas Hoenen, Jiro Yasuda, Haruhisa Inoue. iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility. FEBS open bio. 2021 05; 11(5):1452-1464. doi: 10.1002/2211-5463.13153. [PMID: 33822489]
  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Fang Yang, Nana Li, Mihnea-Alexandru Gaman, Ning Wang. Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: A meta-analysis of randomized controlled trials. Pharmacological research. 2021 04; 166(?):105512. doi: 10.1016/j.phrs.2021.105512. [PMID: 33617974]
  • Eman M Alfadhli. Management of Primary Hyperparathyroidism With Severe Hypercalcemia During the COVID-19 Pandemic. Clinical therapeutics. 2021 04; 43(4):711-719. doi: 10.1016/j.clinthera.2021.02.003. [PMID: 33752899]
  • Katarzyna Szurkowska, Paulina Kazimierczak, Joanna Kolmas. Mg,Si-Co-Substituted Hydroxyapatite/Alginate Composite Beads Loaded with Raloxifene for Potential Use in Bone Tissue Regeneration. International journal of molecular sciences. 2021 Mar; 22(6):. doi: 10.3390/ijms22062933. [PMID: 33805785]
  • Yuan Ma, Yan Zheng, Yanli Ji, Xiuli Wang, Baoxian Ye. Raloxifene, identified as a novel LSD1 inhibitor, suppresses the migration of renal cell carcinoma. Future medicinal chemistry. 2021 03; 13(6):533-542. doi: 10.4155/fmc-2020-0323. [PMID: 33527838]
  • Subin Hong, JuOae Chang, Kwiwan Jeong, Wonsik Lee. Raloxifene as a treatment option for viral infections. Journal of microbiology (Seoul, Korea). 2021 Feb; 59(2):124-131. doi: 10.1007/s12275-021-0617-7. [PMID: 33527314]
  • Patricia Gomez-Gutierrez, Juan J Perez. Discovery of a Bradykinin B2 Partial Agonist Profile of Raloxifene in a Drug Repurposing Campaign. International journal of molecular sciences. 2020 Dec; 22(1):. doi: 10.3390/ijms22010257. [PMID: 33383825]
  • Mohammad Navid Ebrahimi, Mohammad Khaksari, Gholamreza Sepehri, Gholamreza Asadi Karam, Alireza Raji-Amirhasani, Hossein Azizian. The effects of alone and combination tamoxifen, raloxifene and estrogen on lipid profile and atherogenic index of ovariectomized type 2 diabetic rats. Life sciences. 2020 Dec; 263(?):118573. doi: 10.1016/j.lfs.2020.118573. [PMID: 33058909]
  • Ting Du, Rongjin Sun, Li Li, Christabel Ebuzoeme, Dinh Bui, Zicong Zheng, Taijun Yin, Dong Liang, Ming Hu, Song Gao. Development and validation of ultra-high-performance liquid chromatography-mass spectrometry method for the determination of raloxifene and its phase II metabolites in plasma: Application to pharmacokinetic studies in rats. Journal of separation science. 2020 Dec; 43(24):4414-4423. doi: 10.1002/jssc.202000835. [PMID: 33119204]
  • Nimrit Kaur Soni, L J Sonali, Archu Singh, Bharti Mangla, Yub Raj Neupane, Kanchan Kohli. Nanostructured lipid carrier potentiated oral delivery of raloxifene for breast cancer treatment. Nanotechnology. 2020 Nov; 31(47):475101. doi: 10.1088/1361-6528/abaf81. [PMID: 32886644]
  • Karel Smetana, Daniel Rosel, Jan BrÁbek. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality. In vivo (Athens, Greece). 2020 Sep; 34(5):3027-3028. doi: 10.21873/invivo.12135. [PMID: 32871847]
  • Khaled M Hosny, Rahaf H Bahmdan, Nabil A Alhakamy, Mohamed A Alfaleh, Osama A Ahmed, Mohammed H Elkomy. Physically Optimized Nano-Lipid Carriers Augment Raloxifene and Vitamin D Oral Bioavailability in Healthy Humans for Management of Osteoporosis. Journal of pharmaceutical sciences. 2020 07; 109(7):2145-2155. doi: 10.1016/j.xphs.2020.03.009. [PMID: 32194094]
  • Elaine W Yu, Elena Tsourdi, Bart L Clarke, Douglas C Bauer, Matthew T Drake. Osteoporosis Management in the Era of COVID-19. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2020 06; 35(6):1009-1013. doi: 10.1002/jbmr.4049. [PMID: 32406536]
  • Tse-Wei Chen, Johnson Princy Merlin, Shen-Ming Chen, Sathiyan Anandaraj, Mohamed S Elshikh, Tien-Wen Tseng, Kang Wang, Dongdong Qi, Jianzhuang Jiang. Sonochemical synthesis and fabrication of neodymium sesquioxide entrapped with graphene oxide based hierarchical nanocomposite for highly sensitive electrochemical sensor of anti-cancer (raloxifene) drug. Ultrasonics sonochemistry. 2020 Jun; 64(?):104717. doi: 10.1016/j.ultsonch.2019.104717. [PMID: 32062532]
  • Satoshi Takasugi, Miho Shioyama, Masami Kitade, Masashi Nagata, Taketo Yamaji. Involvement of estrogen in phosphorus-induced nephrocalcinosis through fibroblast growth factor 23. Scientific reports. 2020 03; 10(1):4864. doi: 10.1038/s41598-020-61858-7. [PMID: 32184468]
  • Ying Kong, Hui Cai, Han Xing, Chang Ren, Dexuan Kong, Chen Ning, Ning Li, Di Zhao, Xijing Chen, Yang Lu. Pulmonary delivery alters the disposition of raloxifene in rats. The Journal of pharmacy and pharmacology. 2020 Feb; 72(2):185-196. doi: 10.1111/jphp.13201. [PMID: 31730290]
  • Jing-Yi Ye, Zhong-Yun Chen, Chuan-Li Huang, Bei Huang, Yu-Rong Zheng, Ying-Feng Zhang, Ban-Yi Lu, Lin He, Chang-Shun Liu, Xiao-Ying Long. A Non-Lipolysis Nanoemulsion Improved Oral Bioavailability by Reducing the First-Pass Metabolism of Raloxifene, and Related Absorption Mechanisms Being Studied. International journal of nanomedicine. 2020; 15(?):6503-6518. doi: 10.2147/ijn.s259993. [PMID: 32922013]
  • Yanhua Deng, Lin Li, Ceng Li, Fang Wang, Yang Qu. Efficacy of combined medication of risedronate sodium and selective estrogen receptor modulator on the postmenopausal osteoporosis. Pakistan journal of pharmaceutical sciences. 2020 Jan; 33(1(Special)):495-498. doi: . [PMID: 32173648]
  • Nermeen A Elkasabgy, Fatma S Abdel-Salam, Azza A Mahmoud, Emad B Basalious, Mohammed S Amer, Amany A Mostafa, Seham A Elkheshen. Long lasting in-situ forming implant loaded with raloxifene HCl: An injectable delivery system for treatment of bone injuries. International journal of pharmaceutics. 2019 Nov; 571(?):118703. doi: 10.1016/j.ijpharm.2019.118703. [PMID: 31536761]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Hsin-Hsueh Shen, Chien-Yi Yang, Ching-Wen Kung, Shu-Ying Chen, Hong-Min Wu, Pao-Yun Cheng, Kwok-Keung Lam, Yen-Mei Lee. Raloxifene inhibits adipose tissue inflammation and adipogenesis through Wnt regulation in ovariectomized rats and 3 T3-L1 cells. Journal of biomedical science. 2019 Aug; 26(1):62. doi: 10.1186/s12929-019-0556-3. [PMID: 31470850]
  • Sravani Adusumalli, Rohitash Jamwal, R Scott Obach, Tim F Ryder, Lorenzo Leggio, Fatemeh Akhlaghi. Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach. Drug metabolism and disposition: the biological fate of chemicals. 2019 08; 47(8):874-882. doi: 10.1124/dmd.119.087015. [PMID: 31182423]
  • Chitra Choudhary, Amir H Hamrahian, James F Bena, Pablo Recinos, Laurence Kennedy, Georgiana Dobri. THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2019 Jul; 25(7):684-688. doi: 10.4158/ep-2018-0321. [PMID: 30865525]
  • Yukari Uemura, Shiro Tanaka, Teruhiko Miyazaki, Mayumi Tsukiyama, Teruki Sone, Akira Taguchi, Satoshi Soen, Satoshi Mori, Hiroshi Hagino, Toshitsugu Sugimoto, Masao Fukunaga, Hiroaki Ohta, Toshitaka Nakamura, Hajime Orimo, Masataka Shiraki. Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04. Journal of bone and mineral metabolism. 2019 May; 37(3):491-495. doi: 10.1007/s00774-018-0942-z. [PMID: 30019249]
  • Jaleh Varshosaz, Vahab Ziaei, Mohsen Minaiyan, Ali Jahanian-Najafabadi, Leila Sayed-Tabatabaei. Enhanced solubility, oral bioavailability and anti-osteoporotic effects of raloxifene HCl in ovariectomized rats by Igepal CO-890 nanomicelles. Pharmaceutical development and technology. 2019 Feb; 24(2):133-144. doi: 10.1080/10837450.2018.1428815. [PMID: 29338533]
  • Xiao-Yu Qi, Hao Liu, Dong-Dong Bi, Xiang-Tao Wang, Yi-Fei Guo, Ting Hao, Bao-Xin Zhang, Xing-Guo Wang, Mei-Hua Han. Combined administration on You-Gui Yin and low-dose Raloxifene partially attenuates the bone loss in ovariectomized mice through the proliferation and osteogenic differentiation of bone marrow stromal cells. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2019 Feb; 53(?):286-293. doi: 10.1016/j.phymed.2018.09.014. [PMID: 30668409]
  • Anette L Eilertsen, Anders E A Dahm, Else Høibraaten, Cathrine M Lofthus, Marie-Christine Mowinckel, Per M Sandset. Relationship between sex hormone binding globulin and blood coagulation in women on postmenopausal hormone treatment. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2019 Jan; 30(1):17-23. doi: 10.1097/mbc.0000000000000784. [PMID: 30507711]
  • Nabil A Alhakamy, Usama A Fahmy, Osama A A Ahmed. Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene. PloS one. 2019; 14(12):e0226639. doi: 10.1371/journal.pone.0226639. [PMID: 31881053]
  • Young-Seok Lee, Rishab Gupta, Jeong-Taik Kwon, Dae-Chul Cho, Ye Jin Seo, Sung Young Seu, Eui Kyun Park, Inbo Han, Chi-Heon Kim, Joo-Kyung Sung, Kyoung-Tae Kim. Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model. The spine journal : official journal of the North American Spine Society. 2018 10; 18(10):1877-1887. doi: 10.1016/j.spinee.2018.05.020. [PMID: 29793000]
  • Mehrnaz Imani, Mohammad Ebrahim Khamseh, Poopak Asadi, Mohammad Ghorbani, Hamideh Akbari, Fariba Alaei-Shahmiri, Maryam Honardoost, Mahmoud Reza Kaynama, Mojtaba Malek. COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2018 Jun; 24(6):542-547. doi: 10.4158/ep-2017-0195. [PMID: 29949429]
  • Kelsey Connelly, David Collister, Navdeep Tangri. Fracture risk and treatment in chronic kidney disease. Current opinion in nephrology and hypertension. 2018 05; 27(3):221-225. doi: 10.1097/mnh.0000000000000411. [PMID: 29547405]
  • Dan-Dan Tian, Joshua J Kellogg, Neşe Okut, Nicholas H Oberlies, Nadja B Cech, Danny D Shen, Jeannine S McCune, Mary F Paine. Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (Camellia sinensis) Using a Biochemometric Approach: Application to Raloxifene as a Test Drug via In Vitro to In Vivo Extrapolation. Drug metabolism and disposition: the biological fate of chemicals. 2018 05; 46(5):552-560. doi: 10.1124/dmd.117.079491. [PMID: 29467215]
  • Dvora Izgelov, Irina Cherniakov, Gefen Aldouby Bier, Abraham J Domb, Amnon Hoffman. The Effect of Piperine Pro-Nano Lipospheres on Direct Intestinal Phase II Metabolism: The Raloxifene Paradigm of Enhanced Oral Bioavailability. Molecular pharmaceutics. 2018 04; 15(4):1548-1555. doi: 10.1021/acs.molpharmaceut.7b01090. [PMID: 29537855]
  • Jaleh Varshosaz, Mohsen Minaiyan, Ladan Dayyani. Poly(methyl vinyl ether-co-maleic acid) for enhancement of solubility, oral bioavailability and anti-osteoporotic effects of raloxifene hydrochloride. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2018 Jan; 112(?):195-206. doi: 10.1016/j.ejps.2017.11.026. [PMID: 29196024]
  • Divya Vohora, Abul Kalam, Ankita Leekha, Sushama Talegaonkar, Anita Kamra Verma. Combined Raloxifene and Letrozole for Breast Cancer Patients. Archives of medical research. 2017 08; 48(6):561-565. doi: 10.1016/j.arcmed.2017.11.012. [PMID: 29229198]
  • Aline Z Lamas, Andrews M Nascimento, Ana Raquel S Medeiros, Izabela F Caliman, Polyana L M Dalpiaz, Luciana B Firmes, Glauciene J Sousa, Phablo Wendell C Oliveira, Tadeu U Andrade, Adelina M Reis, Sônia A Gouvea, Nazaré S Bissoli. The selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen improve ANP levels and decrease nuclear translocation of NF-kB in estrogen-deficient rats. Pharmacological reports : PR. 2017 Aug; 69(4):798-805. doi: 10.1016/j.pharep.2017.03.004. [PMID: 28591668]
  • A Manni, J P Richie, S E Schetter, A Calcagnotto, N Trushin, C Aliaga, K El-Bayoumy. Stearoyl-CoA desaturase-1, a novel target of omega-3 fatty acids for reducing breast cancer risk in obese postmenopausal women. European journal of clinical nutrition. 2017 06; 71(6):762-765. doi: 10.1038/ejcn.2016.273. [PMID: 28145413]
  • Lisa M Wilson, Casey M Rebholz, Ermias Jirru, Marisa Chi Liu, Allen Zhang, Jessica Gayleard, Yue Chu, Karen A Robinson. Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Annals of internal medicine. 2017 May; 166(9):649-658. doi: 10.7326/m16-2752. [PMID: 28395318]
  • Gianna Ferretti, Tiziana Bacchetti, Luis E Simental-Mendía, Željko Reiner, Maciej Banach, Amirhossein Sahebkar. Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Cardiovascular drugs and therapy. 2017 Apr; 31(2):197-208. doi: 10.1007/s10557-017-6721-6. [PMID: 28265881]
  • Abul Kalam, Sushama Talegaonkar, Divya Vohora. Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice. Molecular and cellular endocrinology. 2017 01; 440(?):34-43. doi: 10.1016/j.mce.2016.11.005. [PMID: 27832985]
  • Adriano Lama, Anna Santoro, Bruno Corrado, Claudio Pirozzi, Orlando Paciello, Teresa Bruna Pagano, Sergio Russo, Antonio Calignano, Giuseppina Mattace Raso, Rosaria Meli. Extracorporeal shock waves alone or combined with raloxifene promote bone formation and suppress resorption in ovariectomized rats. PloS one. 2017; 12(2):e0171276. doi: 10.1371/journal.pone.0171276. [PMID: 28158228]
  • Brian T Palmisano, Lin Zhu, John M Stafford. Role of Estrogens in the Regulation of Liver Lipid Metabolism. Advances in experimental medicine and biology. 2017; 1043(?):227-256. doi: 10.1007/978-3-319-70178-3_12. [PMID: 29224098]
  • Chiaki Tanoue, Kazumi Sugihara, Yoshitaka Tayama, Naoto Uramaru, Yoko Watanabe, Shigeru Ohta, Shigeyuki Kitamura. Variability of Zaleplon 5-Oxidase Activity in Mice and Humans, and Inhibition by Raloxifene. Drug metabolism letters. 2017; 10(4):278-285. doi: 10.2174/1872312810666161227145358. [PMID: 28029084]
  • Betül Yazğan, Yener Yazğan, İshak Suat Övey, Mustafa Nazıroğlu. Raloxifene and Tamoxifen Reduce PARP Activity, Cytokine and Oxidative Stress Levels in the Brain and Blood of Ovariectomized Rats. Journal of molecular neuroscience : MN. 2016 Oct; 60(2):214-22. doi: 10.1007/s12031-016-0785-9. [PMID: 27372663]
  • María E Fernández-Suárez, Joan C Escolà-Gil, Oscar Pastor, Alberto Dávalos, Francisco Blanco-Vaca, Miguel A Lasunción, Javier Martínez-Botas, Diego Gómez-Coronado. Clinically used selective estrogen receptor modulators affect different steps of macrophage-specific reverse cholesterol transport. Scientific reports. 2016 09; 6(?):32105. doi: 10.1038/srep32105. [PMID: 27601313]
  • Camila Tami Stringhetta-Garcia, Monique Patrício Singulani, Leandro Figueiredo Santos, Mário Jefferson Quirino Louzada, Ana Cláudia Stevanato Nakamune, Antonio Hernandes Chaves-Neto, Ana Cláudia Rossi, Edilson Ervolino, Rita Cássia Menegati Dornelles. The effects of strength training and raloxifene on bone health in aging ovariectomized rats. Bone. 2016 Apr; 85(?):45-54. doi: 10.1016/j.bone.2015.11.023. [PMID: 26812611]
  • Narinder Sandhu, Susann E Schetter, Jason Liao, Terryl J Hartman, John P Richie, John McGinley, Henry J Thompson, Bogdan Prokopczyk, Cynthia DuBrock, Carina Signori, Christopher Hamilton, Ana Calcagnotto, Neil Trushin, Cesar Aliaga, Laurence M Demers, Karam El-Bayoumy, Andrea Manni. Influence of Obesity on Breast Density Reduction by Omega-3 Fatty Acids: Evidence from a Randomized Clinical Trial. Cancer prevention research (Philadelphia, Pa.). 2016 Apr; 9(4):275-82. doi: 10.1158/1940-6207.capr-15-0235. [PMID: 26714774]
  • Yanghuan Ye, Tianpeng Zhang, Wan Li, Hua Sun, Danyi Lu, Baojian Wu, Xingwang Zhang. Glucose-Based Mesoporous Carbon Nanospheres as Functional Carriers for Oral Delivery of Amphiphobic Raloxifene: Insights into the Bioavailability Enhancement and Lymphatic Transport. Pharmaceutical research. 2016 Mar; 33(3):792-803. doi: 10.1007/s11095-015-1827-7. [PMID: 26553355]
  • Christopher L Newman, Amy Creecy, Mathilde Granke, Jeffry S Nyman, Nannan Tian, Max A Hammond, Joseph M Wallace, Drew M Brown, Neal Chen, Sharon M Moe, Matthew R Allen. Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease. Kidney international. 2016 Jan; 89(1):95-104. doi: 10.1038/ki.2015.315. [PMID: 26489025]
  • Vinayak Sudhir Jamdade, Nitin A Mundhe, Parveen Kumar, Venkatesh Tadla, Mangala Lahkar. Raloxifene Inhibits NF-kB Pathway and Potentiates Anti-Tumour Activity of Cisplatin with Simultaneous Reduction in its Nephrotoxictiy. Pathology oncology research : POR. 2016 Jan; 22(1):145-53. doi: 10.1007/s12253-015-9988-6. [PMID: 26439246]
  • Susan M Ott. Bone strength: more than just bone density. Kidney international. 2016 Jan; 89(1):16-9. doi: 10.1016/j.kint.2015.11.004. [PMID: 26759040]
  • Hetal P Thakkar, Hitesh Savsani, Praveen Kumar. Ethosomal Hydrogel of Raloxifene HCl: Statistical Optimization & Ex Vivo Permeability Evaluation Across Microporated Pig Ear Skin. Current drug delivery. 2016; 13(7):1111-1122. doi: 10.2174/1567201813666160120151816. [PMID: 26787414]
  • Hayam Ibrahim Gad Allam. Effects of a Combination Therapy of Sclerostin Antibody III and Raloxifene on Bone Formation Markers in Ovariectomized Rats. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2016 Jan; 26(1):46-50. doi: 01.2016/jcpsp.4650. [PMID: 26787031]
  • J E Gomes-Filho, M T Wayama, R C M Dornelles, E Ervolino, G H Yamanari, C S Lodi, G Sivieri-Araújo, E Dezan-Júnior, L T A Cintra. Raloxifene modulates regulators of osteoclastogenesis and angiogenesis in an oestrogen deficiency periapical lesion model. International endodontic journal. 2015 Nov; 48(11):1059-68. doi: 10.1111/iej.12403. [PMID: 25354165]
  • Katsuyuki Nagatoya, Kazuhiko Nishimoto, Nobuhisa Shibahara, Toshikazu Takahashi, Hironori Kanehara, Nobuyuki Ueno, Hideaki Yasuda, Shigeki Okada, Haruhiko Ueda, Kei Hirai, Toru Inoue. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis. Clinical and experimental nephrology. 2015 Oct; 19(5):939-46. doi: 10.1007/s10157-014-1065-z. [PMID: 25504368]
  • Fangqiong Luo, Masatoshi Ishigami, Koichi Achiwa, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Kazuhiko Hayashi, Tetsuya Ishikawa, Yoshiaki Katano, Hidemi Goto. Raloxifene Ameliorates Liver Fibrosis of Nonalcoholic Steatohepatitis Induced by Choline-Deficient High-Fat Diet in Ovariectomized Mice. Digestive diseases and sciences. 2015 Sep; 60(9):2730-9. doi: 10.1007/s10620-015-3660-6. [PMID: 25868633]
  • Brandon T Gufford, Gang Chen, Ana G Vergara, Philip Lazarus, Nicholas H Oberlies, Mary F Paine. Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction. Drug metabolism and disposition: the biological fate of chemicals. 2015 Sep; 43(9):1353-9. doi: 10.1124/dmd.115.065086. [PMID: 26070840]
  • Ying Hui, Lijun Luo, Lingtian Zhang, Katsuhisa Kurogi, Chunyang Zhou, Yoichi Sakakibara, Masahito Suiko, Ming-Cheh Liu. Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis. Journal of pharmacological sciences. 2015 Jul; 128(3):144-9. doi: 10.1016/j.jphs.2015.06.004. [PMID: 26169578]
  • João Eduardo Gomes-Filho, Marcelo Tadahiro Wayama, Rita Cássia Menegati Dornelles, Edilson Ervolino, Gilberto Aparecido Coclete, Paulo Carvalho Tobias Duarte, Guilherme Hiroshi Yamanri, Carolina Simonetti Lodi, Eloi Dezan-Júnior, Luciano Tavares Angelo Cintra. Effect of raloxifene on periapical lesions in ovariectomized rats. Journal of endodontics. 2015 May; 41(5):671-5. doi: 10.1016/j.joen.2014.11.027. [PMID: 25576209]
  • Aline Zandonadi Lamas, Izabela Facco Caliman, Polyana Lima Meireles Dalpiaz, Antônio Ferreira de Melo, Glaucia Rodrigues Abreu, Elenice Moreira Lemos, Sonia Alves Gouvea, Nazaré Souza Bissoli. Comparative effects of estrogen, raloxifene and tamoxifen on endothelial dysfunction, inflammatory markers and oxidative stress in ovariectomized rats. Life sciences. 2015 Mar; 124(?):101-9. doi: 10.1016/j.lfs.2015.01.004. [PMID: 25623855]
  • Sarah A Scott, Cierra T Spencer, Matthew C O'Reilly, Kyle A Brown, Robert R Lavieri, Chul-Hee Cho, Dai-Il Jung, Richard C Larock, H Alex Brown, Craig W Lindsley. Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes. ACS chemical biology. 2015 Feb; 10(2):421-32. doi: 10.1021/cb500828m. [PMID: 25384256]
  • Koji Nakamura, Kenjiro Sawada, Michiyo Sugiyama, Seiji Mabuchi, Takeshi Hisamatsu, Yukihiro Nishio, Kimihiko Ito, Tadashi Kimura, Shoji Kamiura, Ken-ichirou Morishige. Efficacy of raloxifene hydrochloride for the prevention of health care problems in patients who undergo surgery for endometrial cancer: a multicenter randomized clinical trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2015 Feb; 25(2):288-95. doi: 10.1097/igc.0000000000000333. [PMID: 25569817]
  • Jungmee Kim, Ju-Young Shin, Joongyub Lee, Hong-Ji Song, Nam-Kyong Choi, Byung-Joo Park. Comparison of the prescribing pattern of bisphosphonate and raloxifene in Korean women with osteoporosis: from a national health insurance claims database. PloS one. 2015; 10(6):e0127970. doi: 10.1371/journal.pone.0127970. [PMID: 26030300]
  • Deepa Saini, Mohammad Fazil, Mushir M Ali, Sanjula Baboota, Javed Ali. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis. Drug delivery. 2015; 22(6):823-36. doi: 10.3109/10717544.2014.900153. [PMID: 24725026]
  • Farshid Haghverdi, Tahmineh Farbodara, Sepideh Mortaji, Parvin Soltani, Naser Saidi. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5. Iranian journal of kidney diseases. 2014 Nov; 8(6):461-6. doi: . [PMID: 25362221]
  • J Matthew Hutzler, Matthew A Cerny, Young-Sun Yang, Constance Asher, Diane Wong, Kosea Frederick, Kyle Gilpin. Cynomolgus monkey as a surrogate for human aldehyde oxidase metabolism of the EGFR inhibitor BIBX1382. Drug metabolism and disposition: the biological fate of chemicals. 2014 Oct; 42(10):1751-60. doi: 10.1124/dmd.114.059030. [PMID: 25035284]
  • Mélanie Bourque, Marc Morissette, Thérèse Di Paolo. Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Neurobiology of aging. 2014 Oct; 35(10):2347-56. doi: 10.1016/j.neurobiolaging.2014.03.017. [PMID: 24726471]
  • Md Jamir Anwar, K V Radhakrishna, Abhay Sharma, Divya Vohora. Raloxifene preserves phenytoin and sodium valproate induced bone loss by modulating serum estradiol and TGF-β3 content in bone of female mice. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2014 Oct; 62(?):219-26. doi: 10.1016/j.ejps.2014.05.018. [PMID: 24880111]
  • Y Sameena, N Sudha, S Chandrasekaran, Israel V M V Enoch. The role of encapsulation by β-cyclodextrin in the interaction of raloxifene with macromolecular targets: a study by spectroscopy and molecular modeling. Journal of biological physics. 2014 Sep; 40(4):347-67. doi: 10.1007/s10867-014-9355-y. [PMID: 25073419]
  • Somashekhar Battani, Harish Pawar, Sarasija Suresh. Evaluation of oral bioavailability and anticancer potential of raloxifene solid lipid nanoparticles. Journal of nanoscience and nanotechnology. 2014 Aug; 14(8):5638-45. doi: 10.1166/jnn.2014.8872. [PMID: 25935981]